首页> 外国专利> PULMONARY DELIVERY OF RIBAVIRIN OR LEVOVIRIN™ FOR SYSTEMIC AND QUASI-SYSTEMIC TREATMENT OF DISEASE

PULMONARY DELIVERY OF RIBAVIRIN OR LEVOVIRIN™ FOR SYSTEMIC AND QUASI-SYSTEMIC TREATMENT OF DISEASE

机译:利巴韦林或LEVOVIRIN™的肺部输送,用于系统和准系统性疾病的治疗

摘要

A method of treating a systemic viral disease in a patient has a first step in which the disease is correlated with an increase in Type 1 cytokine activity and a decrease in Type 2 activity. In a further step, a systemic dosage of a drug is identified that is effective to increase the Type 1 activity and decrease the type 2 activity, wherein the drug is Ribavirin or Levovirin™ and in a still further step, the dosage of the drug is administered to the patient via pulmonary delivery. A further method of treating a viral disease has a first step in which the disease is correlated with an infection of dendritic cells, and the dendritic cells are targeted by administering Ribavirin or Levovirin™ via a pulmonary aerosol.
机译:治疗患者的全身性病毒性疾病的方法具有第一步,其中该疾病与1型细胞因子活性的增加和2型活性的降低相关。在进一步的步骤中,鉴定了可有效提高1型活性和降低2型活性的药物的全身剂量,其中药物是利巴韦林或Levovirin™,在又一步中,药物的剂量为通过肺部输送给患者。另一种治疗病毒性疾病的方法具有第一步,其中该疾病与树突状细胞的感染有关,并且通过经由肺气雾剂施用利巴韦林或左旋韦林TM来靶向树突状细胞。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号